Malawi shifts vaccine strategy to boost herd immunity against pneumonia
NCT ID NCT04078997
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study in Blantyre, Malawi, compares two schedules of the pneumococcal conjugate vaccine (PCV13): the current 3-dose schedule without a booster (3+0) versus a 2-dose schedule with a booster at 9 months (2+1). The goal is to see if the booster reduces carriage of vaccine-type pneumococcal bacteria in children and adults, thereby improving herd immunity. Over 3,500 participants, including children and HIV-infected adults, will have nasopharyngeal swabs taken to measure bacterial carriage. Results will help Malawi's health officials decide whether to change the national vaccine schedule.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pneumococcal conjugate vaccine 13 (PCV13)
What this could lead to
If successful, this could show that a 2+1 vaccine schedule provides better protection against pneumococcal disease in low-income countries, informing national vaccine policies.
What could go wrong
This is an observational effectiveness study, not a randomized controlled trial, so results may be influenced by other factors. The study is also limited to one district in Malawi, so findings may not apply elsewhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for 13-VALENT PNEUMOCOCCAL VACCINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Malawi-Liverpool-Wellcome Research Programme
Blantyre, Chichiri, P.O. Box 30096, Malawi